Imatinib-induced dermatomyositis sine dermatitis - a rare case report

Front Immunol. 2024 Apr 29:15:1398453. doi: 10.3389/fimmu.2024.1398453. eCollection 2024.


Idiopathic Inflammatory Myopathies are rare conditions with several heterogeneous disease subtypes. They can range from limited muscle or skin involvement to severe, systemic, life-threatening disease. Although the etiology is unknown, some evidence suggests a role for external agents, particularly drugs. Herein, we present a case of a 71-year-old woman with chronic myeloid leukemia who developed imatinib-induced dermatomyositis sine dermatitis. The presentation was predominantly muscular, characterized by proximal muscle weakness and myalgia of the lower limbs, with positive anti-Mi2a antibodies. Spontaneous recovery was observed after drug discontinuation, without the need for immunosuppressive therapy. This is the first confirmed description of an imatinib-induced dermatomyositis sine dermatitis. It reflects the importance of a high awareness from rheumatologists and hematologists to accurately anticipate and identify similar situations.

Keywords: autoantibodies; dermatomyositis sine dermatitis; imatinib mesylate; inflammatory myopathies; proximal muscle weakness.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use
  • Dermatitis / diagnosis
  • Dermatitis / drug therapy
  • Dermatitis / etiology
  • Dermatomyositis* / chemically induced
  • Dermatomyositis* / diagnosis
  • Dermatomyositis* / immunology
  • Female
  • Humans
  • Imatinib Mesylate* / adverse effects
  • Imatinib Mesylate* / therapeutic use
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy

Grants and funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.